Transmembrane protein, Member of the growth arrest-specific 3 (GAS3)/peripheral myelin protein 22 kDa (PMP22) gene family, Four transmembrane domain protein, Related to the tetraspan/transmembrane 4 superfamily (but not a classical tetraspanin)
01
Overview
Epithelial membrane protein 1 (EMP1) is a four-transmembrane-domain protein belonging to the growth arrest-specific 3 (GAS3)/peripheral myelin protein 22 kDa (PMP22) gene family. EMP1 is implicated in key regulatory roles in cell proliferation, cell migration, apoptosis, cell-cell adhesion, and immune microenvironment modulation. In cancer, EMP1 can act both as a promoter of tumor metastasis (such as in prostate cancer and glioblastoma) and as a tumor suppressor (e.g., in nasopharyngeal, esophageal, colorectal, gastric, and ovarian cancers), with its expression variously upregulated or downregulated depending on tumor type and context[1][3][5]. EMP1 may regulate signal transduction and immune cell interactions, affecting tumor immune infiltration. Although no drugs currently target EMP1 clinically, it is under investigation as a novel therapeutic and diagnostic target, and its expression status is proposed as a biomarker for prognosis and tumor immune landscape across multiple tumor types[1][2][3][5].
Other names
B4BTMPEMP-1CL-20Protein B4BTumor-associated membrane protein
02
Mechanism of action
Not applicable; no currently approved drugs. For experimental targeting, mechanisms focus on inhibiting EMP1-mediated cell migration and invasion—potentially via modulation of Rac1, copine-III interaction, or associated signaling pathways (e.g., PI3K/AKT/mTOR, c-myc)
03
Biological functions
Cell migrationCell proliferationRegulation of apoptosisCell-to-cell interactionCell cycle regulationTight junction component in the blood-brain barrierSignal transductionImmune cell infiltration and modulation
No drugs currently approved for clinical use targeting EMP1; therefore, no established drug-specific adverse events.Hypothetical concerns include impact on cell junction integrity, normal cell migration/proliferation, and immune system regulation if EMP1 function is broadly inhibited (inferred from normal roles in tight junctions, neurogenesis, and immune modulation)
06
Interacting drugs
No directly approved or clinical drugs are currently known to specifically target EMP1; ongoing research considers it a putative target in oncology and possibly immunomodulation
07
Biomarkers
EMP1 protein or mRNA overexpression as a prognostic biomarker for poor survival and metastasis in several cancers (notably glioblastoma, prostate cancer, bladder cancer)Reduced EMP1 expression may signify poorer outcomes or more aggressive disease in some epithelial tumors (e.g., colorectal, esophageal, ovarian cancer)Potential marker for immune cell infiltration and tumor microenvironment analyses in specific cancers
Beyond the preview
Go deeper on Epithelial membrane protein 1 (EMP1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epithelial membrane protein 1 (EMP1).